Check out what we’ve been up to and where can we connect!
June 8, 2020
Today, we commit to being better and doing more. We will continue consulting and partnering with the communities where we work, and we will redouble our efforts to ensure that their voices inform and shape the way we do our work. We will reexamine our internal structures and evolve our practices to root out imbalances and inequality and ensure that everyone is represented, included and empowered.
May 22, 2020
Preliminary results of the Adaptive COVID-19 Treatment Trial (ACTT) investigating remdesivir for the treatment of COVID-19 in hospitalized adults with evidence of lower respiratory tract involvement has been published in the New England Journal of Medicine . Of the FHI Clinical study team members, Danielle Fisher, Clinical Research Project Manager, and Wendi McDonald, Associate Project Manager, are listed on the manuscript for her contributions to the study.
April 16, 2020
Our president and CEO, Ted FitzGerald, talks with Outsourcing-Pharma about our partnership with IDRI on an immunotherapy clinical trial to combat COVID-19.
April 3, 2020
FHI Clinical Inc. announces today it has partnered with Infectious Disease Research Institute (IDRI), a Seattle-based not-for-profit organization, to provide full-service contract research organization (CRO) capabilities for an immunotherapy clinical trial to combat moderate to severe cases of COVID-19.
FHI Clinical Headquarters
359 Blackwell Street, Suite 200
Durham, NC 27701 USA